VRTX VERTEX PHARMACEUTICALS INC / MA Insider Trading

EVP/CMO Carmen Bozic sold 1,974 shares of VRTX at $450.00 via 10b5-1 plan; holds 22,760 shares post-sale.

Carmen Bozic, EVP and CMO of Vertex Pharmaceuticals, sold 1,974 shares (22.8K shares remaining, -8.0% vs pre-transaction holdings) at $450.00 on 2026-05-29 as part of a pre-arranged 10b5-1 trading plan. The sale was scheduled under a trading plan, not discretionary. At his prior five trades at VRTX, the 30-day and 90-day post-sale returns were negative across all five instances (ranging from -2.6% to -9.8%), though current price of $425.09 sits -16.3% from the 52-week high. Vertex's fundamentals remain solid with $3.0B in revenue, net income of $1.0B, annual revenue growth of +8.9%, and a market cap of $107.9B.

EVP Carmen Bozic sold 1,354 shares of VRTX at $453.45 under 10b5-1 plan; stock now $434.31, down 14.5% from 52-week high of $507.92.

Carmen Bozic, EVP and CMO, sold 1,354 shares at $453.45 on 2026-05-15 as part of a pre-arranged 10b5-1 trading plan, reducing holdings by -5.2% to 24,734 shares. The current price of $434.31 is down 14.5% from the 52-week high of $507.92, and the stock has declined 1.6% over 30 days and 7.6% over 90 days. Across his prior VRTX trades, Bozic's recent 2026 sales have shown 30-day returns of -4.6%, -9.4%, and -9.8%, while his two 2024 sales at this ticker showed 30-day returns of -1.8% and -1.5%. The scheduled nature of this sale under a 10b5-1 plan indicates predetermined execution rather than discretionary positioning.

EVP/CMO Bozic Carmen sold 6,988 shares of VRTX at $450.00; scheduled 10b5-1 plan, strong track record (66.67% well-timed rate).

Carmen Bozic, EVP and CMO, disposed of 6,988 shares at $450.00 totaling $3,144,600.00 under a pre-arranged 10b5-1 trading plan, meaning this was scheduled execution rather than discretionary conviction. While the sale reduces her holdings from a reported post-transaction level of 26,088 shares, her track record on prior sells shows a 66.67% well-timed rate with an avg 90d return of -1.2%, suggesting her dispositions have historically preceded modest declines. The stock is currently -11.3% from its 52-week high of $507.92 and down -8.4% over 90 days, indicating recent weakness that aligns with her historical patterns. Given the structured nature of the plan and the moderate position retention (26,088 shares remaining), this transaction reflects programmatic portfolio management rather than a bearish strategic signal, though the well-timed historical pattern warrants monitoring.